News

KEYNOTE-564 evaluating Keytruda is the first phase III study to show positive results for adjuvant immunotherapy in renal cell carcinoma.- Merck Inc.,

Read time: 1 mins

Published:5th Jun 2021

Merck Inc., announced first-time results from the pivotal Phase III KEYNOTE-564 trial evaluating Keytruda, Merck’s anti-PD-1 therapy, for the potential adjuvant treatment of patients with renal cell carcinoma (RCC) at intermediate-high or high risk of recurrence following nephrectomy (surgical removal of a kidney) or following nephrectomy and resection of metastatic lesions. After a median follow-up of 24.1 months (14.9-41.5), Keytruda demonstrated a statistically significant and clinically meaningful reduction in the risk of disease recurrence or death by 32% compared to placebo (HR=0.68 [95% CI, 0.53–0.87]; p=0.0010).

Additionally, a favorable trend in overall survival (OS) was observed with a 46% reduction in the risk of death with Keytruda as compared to placebo (HR=0.54 [95% CI, 0.30–0.96]; p=0.0164). As previously announced, the trial will continue to evaluate OS, a key secondary endpoint. The late-breaking results will be presented in the Plenary session of the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting (Abstract #LBA5) on Sunday, June 6, 2021 . As announced, data spanning more than 20 types of cancer will be presented from Merck’s oncology research program at ASCO. A compendium of presentations and posters of Merck-led studies will be posted by Merck on Friday, June 4 at 9 a.m. ET. Follow Merck on Twitter via @Merck and keep up to date with ASCO news and updates by using the hashtag #ASCO21.

Condition: Renal Cell Carcinoma

Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

Cidara Therapeutics reacquires global development and commercial rights to CD 388

Cidara Therapeutics, Inc. a biotechnology company using its proprietary Cloudbreak platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, announced that it has entered into a definitive agreement with Johnson & Johnsonto reacquire the exclusive global development and commercial rights to CD 388, which is in development for the prevention of all strains of influenza A and B

1 mins

Drug news

Cidara Therapeutics announces the divestiture of rezafungin rights to MundiPharma

Cidara Therapeutics, Inc. announced that it has entered into an asset purchase agreement with its current partner, Mundipharma, for the divestiture of rezafungin

1 min

Drug news

FINTEPLA (fenfluramine) oral solution approved in Japan for adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS)

Fintpla (fenfluramine) oral solution has been approved by the Japanese Ministry of Health, Labour, and Welfare (MHLW) for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) as an add-on therapy to other anti-epileptic medicines for patients two years of age and older

1 min

See all news